GT Biopharma appoints Michael Breen as CEO, effective April 29, 2025

GT Biopharma, Inc.

Michael Breen appointed CEO for a two-year term; he had served as Interim CEO since March 2022.
Breen continues as Executive Chairman and Board member, roles held since January and November 2021.
Breen is a UK-qualified solicitor and former senior partner at Clyde & Co., advising biotech clients.
No compensatory terms or changes to existing arrangements disclosed in the filing.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Breen

Chief Executive Officer

GTBP · GT Biopharma, Inc.

Effective: 2025-04-29
Filed: May 5, 2025, 7:59 PM ET

On April 29, 2025, GT Biopharma, Inc. (the “Company”) appointed Michael Breen as its Chief Executive Officer for a two-year term, effective as of April 29, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Breen was appointed as Chief Executive Officer at GT Biopharma, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On April 29, 2025, GT Biopharma, Inc. (the “Company”) appointed Michael Breen as its Chief Executive Officer for a two-year term, effective as of April 29, 2025.

View on SEC.gov

GT Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-008682

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.